Search
Close this search box.
    • Small Molecules
      • Discovery
        Development
        Manufacturing
    • Biologics
      • Discovery
        Development & Manufacturing
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery

      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

        Know More
        Know More
    • Industries
    • Emerging Biopharma

      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

        Know More
        Know More
    • Dedicated Centers

      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

        Know More
        Know More
    • Center for Advanced Protein Studies (CAPS)

      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

        Know More
        Know More
    • Investors
      Corporate Governance
  • Careers
Search
Close this search box.

About Us

Syngene is an integrated research, development, and manufacturing organization providing scientific services from early discovery to commercial supply. Our services cater to a wide range of industrial sectors, including pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical companies. Our culture of scientific innovation is driven by the expertise of our highly qualified team of 6000+ scientists and supported by state-of-the-art infrastructure and market-leading technology.

We offer clients customized, end-to-end solutions to fulfill their R&D and manufacturing requirements. This is underpinned by a well-established safety framework, a track record of quality and compliance, and a robust supply chain. Our approach enables us to forge client relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations due to our shared interest in science and commitment to project delivery.

We recognize that trust is built project-by-project. Hence, we pride ourselves on the many deep, long-term client relationships that underpin our business and demonstrate the value of the work we do.

Our vision

To be a world-class partner delivering innovative scientific solutions

Our values

Integrity

To be ethical, honest and transparent in all we do

Excellence

To commit ourselves to the highest levels of scientific and operational excellence

Professionalism

To practise the highest degree of professionalism by fostering individual accountability, reliability, continuous improvement and customer focus

Our commitment

At Syngene, we aim to contribute to the evolution of scientific research using our skills, technology and experience to find solutions to the world’s most complex challenges.

Clients

Deliver scientific innovation that meets our clients' requirements and, in turn, helps them to meet the needs of the people and patients they serve

Employees

Provide a safe work environment. Offer personal development in scientific, managerial and leadership skills to foster professional growth

Society and Environment

Safeguard the environment by reducing our environmental footprint and producing safe products and supporting the community around us

Our journey

A closer look at our achievements and milestones in the past two decades – with many more to come 

2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology
2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology
2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology
2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology
2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology
2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology
2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology
2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology
2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology
2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology
2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology
2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology
2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology

The journey so far

At Syngene, we aim to contribute to the evolution of scientific research using our skills, technology and experience to find solutions to the world’s most complex challenges. Here is a quick snapshot of our journey so far

2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and biologics development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology

Leadership

Caroline-Hempstead

Caroline Hempstead

Head of Corporate Affairs

Caroline Hempstead has a degree in French studies from Manchester University, UK. She has more than 30 years of experience in Corporate Affairs roles in multinationals in sectors ranging from financial services and oil & gas to pharmaceuticals. She joined Syngene in 2019 as Head of Corporate Affairs. Prior to joining Syngene, she held similar roles at AstraZeneca plc and LafargeHolcim (now Holcim), preceded by leadership roles in corporate communications at Royal Dutch Shell, Inchcape plc and the London Stock Exchange. As a member of the Executive Committee and the ESG Council, her responsibilities encompass corporate communications and Environment, Social and Governance activity.

Andrew-Webster

Andrew Webster

Chief Human Resources Officer

Andrew holds a Business Studies degree from Blackburn College of Technology, UK, and a professional qualification from the Institute of Personnel Management awarded by Salford Technical College, UK. His broad experience in the Human Resources function includes management of mergers and acquisitions; driving culture change; building a leadership and talent pipeline; and delivering a diversity agenda.

Andrew joined Syngene in December 2022 from management consultancy, Teneo, Hong Kong. Prior to joining Teneo he was CHRO for global retail group, DFS and held HR leadership roles at global biopharmaceutical company, AstraZeneca PLC. He started his career as an HR professional in the UK retail groups House of Fraser and Marks and Spencer PLC. Andrew is a member of the Executive Committee.

Joydeep Kant

Senior Vice President – Development Services

Joydeep is an organic chemist with a Ph.D. from the University of Missouri (USA) and postdoctoral training in medicinal-organic chemistry from the University of Kansas School of Pharmacy (USA). Joydeep has over 30 years of experience in global pharmaceutical companies like Zoetis, Pfizer, Bristol-Myers Squibb, Johnson Matthey Pharmaceuticals, and Ranbaxy at various levels. He has a track record of scientific and leadership contributions to human and animal health drug development programs, including drug discovery and manufacturing in the USA and India. Coupled with his passion for science is his distinctive innovation track record, including patents, publications in peer-reviewed journals, monographs, and technical presentations at international symposia, conferences, and academic institutions.

Alex Del Priore

Senior Vice President - Manufacturing

Alex has three decades of experience in developing, commercializing and life-cycle management of products in various life science industries. Holding positions in both the US and Europe, his experience includes senior roles with global P&L responsibility. Alex was Vice President Operations and Health COO at Johnson Matthey in Greater London in his last assignment. In addition, he has been instrumental in M&A, strategy development and new product introduction.

As a member of the Executive Committee, Alex plays a techno-commercial role, providing technical expertise to the API plant at Mangalore while building a sustainable client base for the business in collaboration with the commercial and business development teams. In addition, Alex is also responsible for biologics operations. Alex is based in Center Valley, Pennsylvania, USA.

Kenneth Barr

Senior Vice President – Discovery Services

Kenneth holds a Ph.D. in Synthetic Organic/Organometallic Chemistry from Massachusetts Institute of Technology and has pursued his Postdoctoral study in Natural product synthesis from the University of Texas. He has over two decades of experience in the areas of drug discovery for both small molecules and biologics and has been associated with organisations like Merck, Amplyx Pharmaceuticals Inc. and Sunesis. Prior to joining Syngene, Kenneth was the Head of R&D Strategic Global Operations at FORMA Therapeutics, where he was responsible for driving research effectiveness through optimisation of internal and external R&D research efforts, providing alliance management for key CRO relationships.

Alok Mehrotra

Chief Quality Officer

Alok holds an M. Tech in Chemical Technology (Food Technology) from Harcourt Butler Technological Institute. He comes with more than 25 years of experience spread across Manufacturing Operations, Quality Assurance, Sustainability/EHS, Production, and Supplier Technical Assurance across varied industries. Over the years, Alok has worked with leading corporates, including Dr. Reddy’s, Reckitt Benckiser, Pepsi Foods Ltd,  Godrej Foods, and Beverages Ltd. In his recent assignment as Head of Global Quality Management at Dr. Reddy’s, he harmonized and integrated Quality management systems Globally and was also responsible for quality from all external suppliers and vendors. As Syngene’s CQO, Alok leads the Quality and Compliance function and will be in charge of initiatives to further strengthen our track record in quality and compliance

Sibaji Biswas

Chief Financial Officer

Sibaji is a certified Chartered Financial Analyst (CFA) from ICFAI and holds a B.Tech from IIT- Kharagpur. With an MBA from University of Calcutta he has also completed Management Development Programs at Indian Institute of Management (IIM), Ahmedabad and London Business School. He has over 20 years of extensive experience in finance and related functions. His prior experience includes working with Vodafone (Romania), Vodafone (India), Hutchison Essar Limited, Fascel Limited, and the ABP Group. Prior to joining Syngene, he was the CFO and a member of the Board at Vodafone (Romania). At Syngene, he oversees the finance, supply chain, legal, secretarial and IT functions and as a member of the Executive Committee, he plays an important role in driving strategy, improving profitability, identifying new opportunities, improving cash generation and enabling organizational growth.

Mahesh Bhalgat

Chief Operating Officer

Mahesh holds a Ph.D. in Medicinal Chemistry from the University of Utah, the USA, and a bachelor’s degree in Pharmacy from the University of Mumbai. He has 30 years of experience in the biopharmaceutical, vaccine and pharma industries. Mahesh has worked and led different facets of R&D, analytical development, manufacturing and operations, technology transfer, regulatory sciences, quality and capital projects. During a 20-year US stint, he worked with Amgen, Monsanto, Celera Genomics and Molecular Probes (now Thermo Fisher). After moving to India, Mahesh was part of the team that brought WHO prequalification approvals for four vaccines in Biological E. Just before joining Syngene, he was the Chief Operating Officer at Shantha Biotechnics, a Sanofi company, where his responsibilities included operations, quality, supply chain, long-term strategic planning, manufacturing science and technology and human resources. Mahesh is a member of the CII National Committee on Technology, R&D and Innovation. At Syngene, Mahesh is the Chief Operating Officer and a member of the Executive Committee.

Jonathan Hunt

Managing Director and Chief Executive Officer

Jonathan holds a BA (Business Studies & Economics) degree from the University of Sheffield, United Kingdom and has done his MBA from Durham University, United Kingdom. He is responsible for leading Syngene’s business operations as well as steering its investments in developing and strengthening its capabilities and capacities. He has more than 25 years of extensive experience in the global biopharmaceutical industry. Prior to joining Syngene, he held leadership positions at AstraZeneca for over a decade, including President and Director of AstraZeneca, Austria, and President and Chief Operating Officer, AstraZeneca, India. He has been a member of the Board of Directors of Syngene since 2016 and is a member of the Stakeholders Relationship and ESG Committee, the Risk Management Committee and the Science and Technology Committee.

Dr. Kush Parmar

Independent Director

Dr Parmar holds an MD from Harvard Medical School, a Ph.D. in experimental pathology from Harvard University and a BA in molecular biology and medieval studies from Princeton University. Currently, he is a Managing Partner at 5AM Ventures, a life sciences venture capital firm headquartered in San Francisco. Dr Parmar serves on the Advisory Boards of Harvard Medical School, Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation. At Princeton University, Dr Parmar worked on developmental genetics with Nobel Laureate Eric F. Wieschaus. Dr Parmar also serves on the Boards of Ensoma, Entrada Therapeutics, GlycoEra, Precede, Rallybio, and is a founding member of the COVID R&D alliance. At Syngene, Dr Parmar is a member of the Risk Management Committee and the Science & Technology Committee.

Jonathan Hunt

Managing Director and Chief Executive Officer

Mr Hunt has over 30 years of experience in the global life sciences and biopharmaceuticals industry. At Syngene, he is responsible for strategy, strategy execution, leading the executive team and the Company’s business operations and steering its investment decisions.

Prior to joining Syngene, he held leadership positions at AstraZeneca for over a decade, including President and Director of AstraZeneca, Austria, and President and Chief Operating Officer, AstraZeneca, India. He has been a member of the Board of Directors of Syngene since 2016 and is a member of the Stakeholders Relationship & ESG Committee, the Risk Management Committee and the Science & Technology Committee.

He completed his BA in Business Studies & Economics from the University of Sheffield and holds an MBA from Durham University, United Kingdom

Sharmila Karve

Independent Director

Ms Sharmila Abhay Karve is a Fellow of the Institute of Chartered Accountants of India. She retired as audit partner from Price Waterhouse in June 2019. During her tenure in Price Waterhouse, she was an engagement partner with several large Indian and multinational clients. She was appointed as the Chief Ethics Officer. In 2009, she was appointed as the Assurance Leader of the firm and was elevated to the role of Assurance Risk & Quality Leader in April 2012. In her last role as Global Diversity Leader since December 2016, Ms. Karve focussed her efforts on bringing more diversity throughout the PwC network. At present, she is a Director on the boards of CSB Bank Limited, EPL Limited, Vanaz Engineers Limited, Aadhar Housing Finance Limited and Thomas Cook (India) Limited in India. Her overseas directorships include Fairfax India Holdings Corporation, EPL Packaging (Guangzhou) Ltd., EPL America LLC, and Lamitube Technology Ltd, Mauritius. At Syngene, she is the Chairperson of the Stakeholders Relationship & ESG Committee and a member of the Audit

Dr. Carl Decicco

Independent Director

Dr Decicco retired on January 11, 2022 as the Chief Scientific Officer at Foghorn Therapeutics in Cambridge MA after serving in the position for three years. Prior to joining Foghorn in 2018, he served as the Head of Discovery at Bristol Myers Squibb (BMS). He is a Partner at Flagship Pioneering and serves on the Board of Cellarity Pharmaceuticals. Dr Decicco completed postdoctoral studies with Professor EJ Corey at Harvard University, was a teaching fellow at the University of British Columbia and obtained his Ph.D. with Professor Gordon Lange in Organic Chemistry from the Guelph-Waterloo Center in Ontario, Canada. At Syngene, he is a member of the Risk Management Committee and the Science & Technology Committee.

Vinita Bali

Lead Independent Director

Ms Bali is a global business leader with extensive experience in leading and transforming large companies both in India and overseas. She served as Chief Executive Officer & MD of Britannia Industries Ltd., from 2005 to 2014. Prior to that, she worked for The Coca-Cola Company and Cadbury Schweppes Plc in a variety of Marketing, General Management and Chief Executive roles in the UK, Nigeria, South Africa, USA and Chile. At present, she is a Non-Executive Director on the global boards of SATS Ltd and Cognizant Technology Solutions, and in India, she serves on the board of CRISIL Ltd – an S&P Company. At Syngene, she is the Chairperson of the Nomination & Remuneration Committee and a member of the Audit Committee and the Corporate Social Responsibility Committee.

Dr. Vijay Kuchroo

Independent Director

Dr Kuchroo has a doctorate in Pathology from the University of Queensland, Australia. He is also the Samuel L. Wasserstrom Professor of Neurology at the Harvard Medical School, Senior Scientist at the Brigham and Women’s Hospital and Institute Member at the Broad Institute of MIT and Harvard, all in the United States. Dr Kuchroo has won many awards for the discovery of TIM-3 ‘checkpoint’ molecules for cancer immunotherapy and Th17 cells in the induction of autoimmunity. Dr Kuchroo holds over 50 patents and has published over 400 research papers in immunology. He is a member of the scientific advisory boards of leading pharmaceutical companies, including Pfizer, Novartis, Sanofi and GSK. He has founded eight biotech companies, including CoStim Pharmaceuticals and Tempero Pharmaceuticals. At Syngene, Dr Kuchroo is the Chairman of the Science & Technology Committee and a member of the Nomination & Remuneration Committee and the Corporate Social Responsibility Committee.

Paul Blackburn

Independent Director

Mr Blackburn has a BSc in Management Sciences from Warwick University, United Kingdom, and a professional accounting qualification from the Chartered Institute of Management Accountants, United Kingdom. With more than 40 years’ experience in the field of finance, he worked as a senior finance executive at GlaxoSmithKline in the UK. Mr Blackburn also served on the Board of Mereo Biopharmaceuticals, UK, and chaired the Audit and Risk Committee for five years ending 1st October, 2020. At Syngene, Mr Blackburn is Chairman of the Audit Committee and the Risk Management Committee and a member of the Stakeholders Relationship & ESG Committee.

Professor Catherine Rosenberg

Non-Executive Director

Professor Rosenberg is the Canada Research Chair in the Future Internet, the Cisco Research Chair in 5G Systems and a professor in electrical and computer engineering at the University of Waterloo, Canada. She is a Fellow of the Institute of Electrical and Electronics Engineers and of the Canadian Academy of Engineering. At Syngene, she is Chairperson of the Corporate Social Responsibility Committee, and a member of the Nomination & Remuneration Committee, the Stakeholders

Relationship & ESG Committee and the Science & Technology Committee.

Kiran Mazumdar Shaw

Non-Executive Chairperson

Ms. Shaw is a first-generation entrepreneur with over 45 years of experience in the field of biotechnology. She is a recipient of ‘Padma Shri’ and the ‘Padma Bhushan’ awards. She was also conferred with the highest French distinction – Chevalier de l’Ordre national de la Legion d’honneur (Knight of the Legion of Honour) in 2016. She is a recipient of ICMR’s Lifetime Achievement Award for Outstanding Achievement in Healthcare in 2019. She was Honoured with Order of Australia, Australia’s highest civilian award and was named EY World Entrepreneur of the year in 2020. She is also the Chairperson of Biocon Limited, Independent Director on the Board of United Breweries Ltd and Narayana Hrudayalaya.

Awards and recognitions

Awards and recognitions

More
More
Our manufacturing and quality certifications

Certifications

We deliver our services with the highest regard for safety and regulatory compliance. Syngene has certifications from global regulatory authorities for our state-of-the-art facilities and across process and quality management systems.

More
More
Our manufacturing and quality certifications
The Principles of the Quality Management System adopted by our company

Quality management

Syngene is committed to offering various scientific research and development services that meet or exceed client expectations. All our services are in compliance with national and international regulatory requirements.

More
More
Syngene’s Approach To Environment Health Safety And Sustainability (EHSS)

Environment, health, safety & sustainability

Syngene considers environment, health, safety & sustainability (EHSS) excellence as a top priority in all of its processes and is fully committed to achieving it in the most responsible manner.

More
More
Syngene’s Approach To Environment Health Safety And Sustainability (EHSS)
Our Research And Development Centers | Syngene CRO

Infrastructure

Syngene has world-class infrastructure with more than 1.87 million sq ft. of working space. Syngene strives to attract and retain the best talent in the industry and back them up with world class infrastructure and systems.

More
More
We pursue our Corporate Social Responsibility (CSR) with the same passion and responsibility as we do it with scientific research

Corporate social responsibility

We strive towards developing and sustaining healthy and empowered communities by improving the quality of life. We pursue corporate social responsibility with the same passion and responsibility as scientific research.

More
More

Join Syngene
Be at the cutting-edge of scientific innovation

View all opportunities
View All Opportunities

Sign-up for our newsletter

© 2023. Syngene International Limited

Twitter Linkedin-in Youtube Facebook-f

Quick Links

Business

Get In Touch

Other Links
Twitter Linkedin-in Youtube Facebook-f

© 2023. Syngene International Limited

Download PDF
Download PDF

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements. To find out more, read our Privacy Policy and Cookies Policy. and
Close

To view or email, Please share your details view

To download, Please share your details